Abstract

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)
Paul G Richardson ... Kenneth C Anderson
Blood | VOL. 126
Paul G Richardson, et. al.Paul G Richardson ... Kenneth C Anderson
03 Dec 2015
Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease
Joshua Richter ... Philippe Moreau
Blood | VOL. 138
Joshua Richter, et. al.Joshua Richter ... Philippe Moreau
05 Nov 2021
Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update
Ajai Chari ...
Blood | VOL. 134
Ajai Chari, et. al.Ajai Chari ...
13 Nov 2019
Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study
Shambavi Richard ...
Blood | VOL. 136
Shambavi Richard, et. al.Shambavi Richard ...
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis.
Ayalew Tefferi ... Tiziano Barbui
Blood | VOL. -
Ayalew Tefferi, et. al.Ayalew Tefferi ... Tiziano Barbui
08 Aug 2024
CDK9 phosphorylates RUNX1 to promote megakaryocytic fate in megakaryocytic-erythroid progenitors.
Nayoung Kwon ... Diane S Krause
Blood | VOL. -
Nayoung Kwon, et. al.Nayoung Kwon ... Diane S Krause
05 Aug 2024
Asciminib Monotherapy as Frontline Treatment of Chronic Phase Chronic Myeloid Leukaemia – Results from the ASCEND Study
David T Yeung ... Timothy P Hughes
Blood | VOL. -
David T Yeung, et. al.David T Yeung ... Timothy P Hughes
05 Aug 2024
Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.
Esteban Arrieta-Bolaños ... Katharina Fleischhauer
Blood | VOL. -
Esteban Arrieta-Bolaños, et. al.Esteban Arrieta-Bolaños ... Katharina Fleischhauer
05 Aug 2024
View more papers